Aprea Therapeutics Climbs 3% On Positive Study Results Of Its Lead Drug

(RTTNews) - Shares of biopharmaceutical company Aprea Therapeutics, Inc. (APRE) are climbing more than 3% Wednesday morning after it announced positive results from the mid-stage study evaluating eprenetapopt, the company's lead drug candidate, with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

During the Phase 2 study, patients treated with eprenetapopt plus azacitidine, the relapse free survival (RFS) at 1 year post-transplant was 58% and the median RFS was 12.1 months. The overall survival (OS) at 1 year post-transplant was 79%, with a median OS of 19.3 months.

APRE, currently at $5.23, has traded in the range of $3.88- $31.45 in the last 52 weeks.